Clinical trial NCT06630650: A Prospective Natural History and Outcome Measure Validation Study of Congenital Myasthenic Syndromes
Official title: A Single Center Prospective Natural History and Outcome Measure Validation Study of Congenital Myasthenic Syndromes
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Myasthenic Syndromes, Congenital
Keywords: Congenital Myasthenic Syndrome
Collagen Q
Downstream of tyrosine kinase 7
DOK7
COLQ
Lead sponsor: National Institutes of Health Clinical Center (CC)
Sponsor class: NIH
First posted: 2024-10-08
Enrollment: 75
Sex: ALL
Minimum age (years): 6
Maximum age (years): 99
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with congenital myasthenic syndromes with a focus on DOK7 and COLQ subtypes.

Brief summary: Background:

Congenital myasthenic syndromes (CMSs) are a group of inherited disorders that affect how the nerves communicate with muscles. These can cause many problems that affect how people can move and use their bodies.

Objective:

This is a natural history study to learn more about how CMSs affect the body and cause changes over time.

Eligibility:

People aged 6 months or older with a CMS. The study will focus on DOK7- and COLQ-related CMSs, as well as other forms.

Design:

Participants will have up to 7 visits in 5 years. At each visit, participants will undergo many tests, including:

Physical exam with blood and urine tests.

Tests of their heart and lung function.

Exams of the eyes, lungs, muscles, and nerves. These will be done with different specialists.

Exams of the arms and hands and of body use and movements. These will also be done with specialists.

Photos and videos may be taken.

Muscle ultrasound. Participants will lie still as a wand is rubbed over their skin.

Magnetic resonance imaging (MRI) scans. Participants will lie still on a bed that slides partway into a large tube. A parent or other person may remain in the room, too. The scan will take 60 minutes.

Electromyography (EMG). Participants will lie still or may be asked to move around. A machine will measure the electrical activity in their muscles.

An activity monitor may be placed on the participant s wrist, ankle, or hip for up to 2 weeks. The monitor is about the size of a wristwatch.

A sample of skin may be removed....

Detailed description: Study Description:

This natural history and outcome measure validation study aims to longitudinally characterize the clinical manifestations of all congenital myasthenic syndromes (CMS), with a focus on DOK7 and COLQ-related CMS. Both are ultra-rare inherited disorders of the neuromuscular junction. This study will also assess the validity and interrater reliability of outcome measures to support clinical trial readiness in these populations.

Primary Objective:

Characterize baseline clinical manifestations and CMS disease course over one year.

Co-Primary Objective:

Assess the validity and interrater reliability of outcome measures in CMS.

Secondary Objectives:

Characterize the extended disease course of CMS (Years 2 through 5)

Exploratory Objectives:

Biomarker identification, accelerometer validation, and MCID estimation.

Primary Endpoints:

Change from baseline to Year 1 in the following (as age-appropriate and tolerated-performed in all participants unless age ranges specified):

* Physical strength

  * MRC scale (all; as tolerated/developmentally appropriate)
  * Quantitative muscle assessment of shoulder abductors, elbow flexors/extensors, hip flexors and knee extensors/flexors (QMA \>=7y)
  * Myotools grip and pinch strength (\>=6y)
* Physical performance

  * Six-minute walk test distance (\>=6y)
  * Repeated 1 minute sit to stand (\>=2y)
  * Performance of Upper Limb (PUL) (\>=2y)
  * Time of outstretched arm (\>=2y)
* Disease severity

  --Quantitative Myasthenia Gravis (QMG) Score (\>= 12y)
* Motor function \<2y

  * Hammersmith infant neurological scale score (\<2y)
  * Sitting balance score (\<2y)
* Motor function \>2y

  * Motor function measure score (MFM20, 2-6y) (MFM32, \>=7y)
  * Time to ascend four stairs, descend four stairs, supine to stand (\>=5y)
* Development

  --Developmental motor scale quotients (\<5y)
* Pulmonary function \>=5y

  * Forced vital capacity (FVC)
  * Slow vital capacity (SVC)
  * Forced vital capacity at 1 second (FEV1)
  * Maximum inspiratory and expiratory pressures (MIP/MEP)
  * End-tidal CO2 (ETCO2)
* Quality of life

  * Myasthenia Quality of Life (PM-QOL15 \<18y, MG-QOL15 \>=18)
  * PROMIS-57 Profile (\>=18y)
  * PROMIS Ped-25 Profile (8-17y)
  * PROMIS Parent Proxy CAT (5-7y)
  * NeuroQoL (fatigue and upper and lower limb function domains, (\>=8y)
  * MG-ADL (\>=18y)
* Serious adverse and disease-related events

  * Narrative clinician description
  * Causality assessment (related or unrelated to the research or disease)
  * Event severity (CTCAE v5)
  * Event MedDRA system organ class, and preferred term

Co-Primary Endpoints:

Interrater reliability in physical strength, physical performance, motor function, and quality of life primary endpoints.

Secondary Endpoints:

Change over time in primary endpoints (Years 2 through 5).

Exploratory Endpoints:

* Physical performance

  * Timed up and go (TUG) test x3 (\>=2y)
  * Wearable sensor metrics during physical performance tests
* Biomechanics

  * Stride length, cadence, velocity captured in clinic by wearable device
  * Stride velocity 95th centile
* Free-living physical activity

  * Endpoints collected over 2-week data capture period will include:
  * Number of sit-to-stand transitions
  * Step count
  * Average cadence per walking episode
  * Number of falls
  * Activity counts (light, moderate, vigorous, moderate to vigorous)
  * Upper limb movements
  * Proposal to use in infants/toddlers, use of one device/chest strap.
* Ophthalmology

  * Marginal reflex distance (Ptosis)
  * Pupillometry
  * Ocular Motility utilizing Modified Goldmann Perimeter per NEI
* Quality of life

  * CMS-ST- Infant/Young Child 6 months - \<=3 years of age
  * CMS-ST Child/Adult (4 years - \<=18 years)
* Biomarkers

  * Peripheral biomarkers
  * Optional skin punch biopsy (fibroblast culture)
* Imaging

  * Muscle MRI lower extremities (T1 and Dixon)
  * Muscle ultrasound (echogenicity)
* Nerve function

  --EMG/NCS (sfEMG and RNS)
* Measurement of AE burden

  * Adverse Event Unit (AEU)

Eligibility criteria: * INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

* Stated willingness to comply with all study procedures and availability for the duration of the study
* Male or female, aged \>= 6 months of age
* Clinically stable as evidenced by medical record review and remote screening questionnaire
* Genetically confirmed congenital myasthenic syndrome (pathogenic or likely pathogenic variants identified by CLIA testing in an established CMS-related gene including but not limited to DOK7, COLQ, CHRNE, RAPSN, CHAT, GFPT1, DPAGT1 OR pathogenic/likely pathogenic variant in combination with a variant of uncertain significance (VUS) AND additional clinical supporting evidence of CMS).
* Agreement to adhere to Lifestyle Considerations throughout study duration
* Ability of subject to understand and the willingness to provide informed consent (\>=18 years of age) and assent (\>=7 years of age).

EXCLUSION CRITERIA:

* Received gene transfer therapy
* Pregnant women (prior to enrollment)
* Ongoing medical condition or medication use that is deemed by the Principal Investigator to interfere with the conduct or assessments of the study or safety of the subject.

Primary outcomes:
measure: Characterize baseline clinical manifestations and CMS disease
timeFrame: One year
measure: Assess the validity and interrater reliability of outcome measures in CMS
timeFrame: 5 Years
Secondary outcomes:
measure: Characterize the extended disease course of CMS
timeFrame: Years 2-5
Other outcomes:
Locations:
city: Bethesda
country: United States
facility: National Institutes of Health Clinical Center
state: Maryland
Study officials:
affiliation: National Institute of Neurological Disorders and Stroke (NINDS)
name: Carsten G Bonnemann, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Brooks PJ, Ottinger EA, Portero D, Lomash RM, Alimardanov A, Terse P, Xu X, Chandler RJ, Geist Hauserman J, Esposito E, Bonnemann CG, Venditti CP, Austin CP, Pariser A, Lo DC. The Platform Vector Gene Therapies Project: Increasing the Efficiency of Adeno-Associated Virus Gene Therapy Clinical Trial Startup. Hum Gene Ther. 2020 Oct;31(19-20):1034-1042. doi: 10.1089/hum.2020.259. No abstract available.
citation: Nicole S, Azuma Y, Bauche S, Eymard B, Lochmuller H, Slater C. Congenital Myasthenic Syndromes or Inherited Disorders of Neuromuscular Transmission: Recent Discoveries and Open Questions. J Neuromuscul Dis. 2017;4(4):269-284. doi: 10.3233/JND-170257.
citation: Maggi L, Bernasconi P, D'Amico A, Brugnoni R, Fiorillo C, Garibaldi M, Astrea G, Bruno C, Santorelli FM, Liguori R, Antonini G, Evoli A, Bertini E, Rodolico C, Mantegazza R. Italian recommendations for diagnosis and management of congenital myasthenic syndromes. Neurol Sci. 2019 Mar;40(3):457-468. doi: 10.1007/s10072-018-3682-x. Epub 2018 Dec 15.
citation: Bergamin E, Hallock PT, Burden SJ, Hubbard SR. The cytoplasmic adaptor protein Dok7 activates the receptor tyrosine kinase MuSK via dimerization. Mol Cell. 2010 Jul 9;39(1):100-9. doi: 10.1016/j.molcel.2010.06.007.
citation: Sigoillot SM, Bourgeois F, Lambergeon M, Strochlic L, Legay C. ColQ controls postsynaptic differentiation at the neuromuscular junction. J Neurosci. 2010 Jan 6;30(1):13-23. doi: 10.1523/JNEUROSCI.4374-09.2010.
citation: Hallock PT, Xu CF, Park TJ, Neubert TA, Curran T, Burden SJ. Dok-7 regulates neuromuscular synapse formation by recruiting Crk and Crk-L. Genes Dev. 2010 Nov 1;24(21):2451-61. doi: 10.1101/gad.1977710.
citation: Palace J, Lashley D, Newsom-Davis J, Cossins J, Maxwell S, Kennett R, Jayawant S, Yamanashi Y, Beeson D. Clinical features of the DOK7 neuromuscular junction synaptopathy. Brain. 2007 Jun;130(Pt 6):1507-15. doi: 10.1093/brain/awm072. Epub 2007 Apr 23.
citation: Lee M, Beeson D, Palace J. Therapeutic strategies for congenital myasthenic syndromes. Ann N Y Acad Sci. 2018 Jan;1412(1):129-136. doi: 10.1111/nyas.13538.
citation: McMacken GM, Spendiff S, Whittaker RG, O'Connor E, Howarth RM, Boczonadi V, Horvath R, Slater CR, Lochmuller H. Salbutamol modifies the neuromuscular junction in a mouse model of ColQ myasthenic syndrome. Hum Mol Genet. 2019 Jul 15;28(14):2339-2351. doi: 10.1093/hmg/ddz059.
citation: James MA. Use of the Medical Research Council muscle strength grading system in the upper extremity. J Hand Surg Am. 2007 Feb;32(2):154-6. doi: 10.1016/j.jhsa.2006.11.008. No abstract available.
citation: Fernandez-Rhodes LE, Kokkinis AD, White MJ, Watts CA, Auh S, Jeffries NO, Shrader JA, Lehky TJ, Li L, Ryder JE, Levy EW, Solomon BI, Harris-Love MO, La Pean A, Schindler AB, Chen C, Di Prospero NA, Fischbeck KH. Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. Lancet Neurol. 2011 Feb;10(2):140-7. doi: 10.1016/S1474-4422(10)70321-5. Epub 2011 Jan 6.
citation: Bortolani S, Brusa C, Rolle E, Monforte M, De Arcangelis V, Ricci E, Mongini TE, Tasca G. Technology outcome measures in neuromuscular disorders: A systematic review. Eur J Neurol. 2022 Apr;29(4):1266-1278. doi: 10.1111/ene.15235. Epub 2022 Jan 10.
citation: Bruggeman BS, Vincent HK, Chi X, Filipp SL, Mercado R, Modave F, Guo Y, Gurka MJ, Bernier A. Simple tests of cardiorespiratory fitness in a pediatric population. PLoS One. 2020 Sep 4;15(9):e0238863. doi: 10.1371/journal.pone.0238863. eCollection 2020.
citation: Servais L, Mercuri E, Straub V, Guglieri M, Seferian AM, Scoto M, Leone D, Koenig E, Khan N, Dugar A, Wang X, Han B, Wang D, Muntoni F; SKIP-NMD Study Group. Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial. Nucleic Acid Ther. 2022 Feb;32(1):29-39. doi: 10.1089/nat.2021.0043. Epub 2021 Nov 17.
citation: de Lattre C, Payan C, Vuillerot C, Rippert P, de Castro D, Berard C, Poirot I; MFM-20 Study Group. Motor function measure: validation of a short form for young children with neuromuscular diseases. Arch Phys Med Rehabil. 2013 Nov;94(11):2218-26. doi: 10.1016/j.apmr.2013.04.001. Epub 2013 Apr 18.
citation: Berard C, Payan C, Hodgkinson I, Fermanian J; MFM Collaborative Study Group. A motor function measure for neuromuscular diseases. Construction and validation study. Neuromuscul Disord. 2005 Jul;15(7):463-70. doi: 10.1016/j.nmd.2005.03.004.
citation: Tindall RS, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med. 1987 Mar 19;316(12):719-24. doi: 10.1056/NEJM198703193161205.
citation: Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci. 1998 May 13;841:769-72. doi: 10.1111/j.1749-6632.1998.tb11015.x. No abstract available.
citation: Griffiths A, Toovey R, Morgan PE, Spittle AJ. Psychometric properties of gross motor assessment tools for children: a systematic review. BMJ Open. 2018 Oct 27;8(10):e021734. doi: 10.1136/bmjopen-2018-021734.
citation: Richardson C, Smith T, Schaefer A, Turnbull D, Griffiths P. Ocular motility findings in chronic progressive external ophthalmoplegia. Eye (Lond). 2005 Mar;19(3):258-63. doi: 10.1038/sj.eye.6701488.
citation: Chiang J, Mehta K, Amin R. Respiratory Diagnostic Tools in Neuromuscular Disease. Children (Basel). 2018 Jun 15;5(6):78. doi: 10.3390/children5060078.
citation: Della Marina A, Wibbeler E, Abicht A, Kolbel H, Lochmuller H, Roos A, Schara U. Long Term Follow-Up on Pediatric Cases With Congenital Myasthenic Syndromes-A Retrospective Single Centre Cohort Study. Front Hum Neurosci. 2020 Dec 7;14:560860. doi: 10.3389/fnhum.2020.560860. eCollection 2020.
citation: Prior DE, Cooper BA, Zhang B, Ghosh PS. Developing outcome measures of disease activity in pediatric myasthenia. Muscle Nerve. 2021 May;63(5):751-757. doi: 10.1002/mus.27208. Epub 2021 Feb 28.
citation: Cella D, Choi SW, Condon DM, Schalet B, Hays RD, Rothrock NE, Yount S, Cook KF, Gershon RC, Amtmann D, DeWalt DA, Pilkonis PA, Stone AA, Weinfurt K, Reeve BB. PROMIS(R) Adult Health Profiles: Efficient Short-Form Measures of Seven Health Domains. Value Health. 2019 May;22(5):537-544. doi: 10.1016/j.jval.2019.02.004.
citation: Cox ED, Connolly JR, Palta M, Rajamanickam VP, Flynn KE. Reliability and validity of PROMIS(R) pediatric family relationships short form in children 8-17 years of age with chronic disease. Qual Life Res. 2020 Jan;29(1):191-199. doi: 10.1007/s11136-019-02266-x. Epub 2019 Aug 10.
citation: Varni JW, Thissen D, Stucky BD, Liu Y, Magnus B, Quinn H, Irwin DE, DeWitt EM, Lai JS, Amtmann D, Gross HE, DeWalt DA. PROMIS(R) Parent Proxy Report Scales for children ages 5-7 years: an item response theory analysis of differential item functioning across age groups. Qual Life Res. 2014 Feb;23(1):349-61. doi: 10.1007/s11136-013-0439-0. Epub 2013 Jun 6.
citation: Finlayson S, Morrow JM, Rodriguez Cruz PM, Sinclair CD, Fischmann A, Thornton JS, Knight S, Norbury R, White M, Al-Hajjar M, Carboni N, Jayawant S, Robb SA, Yousry TA, Beeson D, Palace J. Muscle magnetic resonance imaging in congenital myasthenic syndromes. Muscle Nerve. 2016 Aug;54(2):211-9. doi: 10.1002/mus.25035. Epub 2016 Feb 22.
citation: Ramdas S, Beeson D. Congenital myasthenic syndromes: where do we go from here? Neuromuscul Disord. 2021 Oct;31(10):943-954. doi: 10.1016/j.nmd.2021.07.400.
citation: Benatar M, Sanders DB, Burns TM, Cutter GR, Guptill JT, Baggi F, Kaminski HJ, Mantegazza R, Meriggioli MN, Quan J, Wolfe GI; Task Force on MG Study Design of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Recommendations for myasthenia gravis clinical trials. Muscle Nerve. 2012 Jun;45(6):909-17. doi: 10.1002/mus.23330.
citation: Troha Gergeli A, Neubauer D, Golli T, Butenko T, Loboda T, Maver A, Osredkar D. Prevalence and genetic subtypes of congenital myasthenic syndromes in the pediatric population of Slovenia. Eur J Paediatr Neurol. 2020 May;26:34-38. doi: 10.1016/j.ejpn.2020.02.002. Epub 2020 Feb 11.
citation: Pane M, Coratti G, Brogna C, Mazzone ES, Mayhew A, Fanelli L, Messina S, D'Amico A, Catteruccia M, Scutifero M, Frosini S, Lanzillotta V, Colia G, Cavallaro F, Rolle E, De Sanctis R, Forcina N, Petillo R, Barp A, Gardani A, Pini A, Monaco G, D'Angelo MG, Zanin R, Vita GL, Bruno C, Mongini T, Ricci F, Pegoraro E, Bello L, Berardinelli A, Battini R, Sansone V, Albamonte E, Baranello G, Bertini E, Politano L, Sormani MP, Mercuri E. Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data. PLoS One. 2018 Jun 20;13(6):e0199223. doi: 10.1371/journal.pone.0199223. eCollection 2018.
citation: Mayhew AG, Coratti G, Mazzone ES, Klingels K, James M, Pane M, Straub V, Goemans N, Mercuri E; Pul Working Group. Performance of Upper Limb module for Duchenne muscular dystrophy. Dev Med Child Neurol. 2020 May;62(5):633-639. doi: 10.1111/dmcn.14361. Epub 2019 Sep 19.
citation: Pierzchlewicz K, Kepa I, Podogrodzki J, Kotulska K. Spinal Muscular Atrophy: The Use of Functional Motor Scales in the Era of Disease-Modifying Treatment. Child Neurol Open. 2021 Apr 27;8:2329048X211008725. doi: 10.1177/2329048X211008725. eCollection 2021 Jan-Dec.
citation: Burns TM, Sadjadi R, Utsugisawa K, Gwathmey KG, Joshi A, Jones S, Bril V, Barnett C, Guptill JT, Sanders DB, Hobson-Webb L, Juel VC, Massey J, Gable KL, Silvestri NJ, Wolfe G, Cutter G, Nagane Y, Murai H, Masuda M, Farrugia ME, Carmichael C, Birnbaum S, Hogrel JY, Nafissi S, Fatehi F, Ou C, Liu W, Conaway M. International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r. Muscle Nerve. 2016 Dec;54(6):1015-1022. doi: 10.1002/mus.25198. Epub 2016 Nov 7.
citation: Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999 Apr 22;52(7):1487-9. doi: 10.1212/wnl.52.7.1487.
citation: Ousmen A, Touraine C, Deliu N, Cottone F, Bonnetain F, Efficace F, Bredart A, Mollevi C, Anota A. Distribution- and anchor-based methods to determine the minimally important difference on patient-reported outcome questionnaires in oncology: a structured review. Health Qual Life Outcomes. 2018 Dec 11;16(1):228. doi: 10.1186/s12955-018-1055-z.
citation: Cornett KMD, Menezes MP, Bray P, Shy RR, Moroni I, Pagliano E, Pareyson D, Estilow T, Yum SW, Bhandari T, Muntoni F, Laura M, Reilly MM, Finkel RS, Eichinger KJ, Herrmann DN, Shy ME, Burns J; CMTPedS Study Group. Refining clinical trial inclusion criteria to optimize the standardized response mean of the CMTPedS. Ann Clin Transl Neurol. 2020 Sep;7(9):1713-1715. doi: 10.1002/acn3.51145. Epub 2020 Aug 6.